



Mesoblast to Present at the 34th Annual J. P. Morgan Healthcare Conference

Melbourne, Australia; and New York, USA; 8 January 2016: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that it will present at the 34th Annual J. P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday 13 January 2016, at 3.30 p.m. PST/10.30am Thursday 14 January 2016 (AEDT).

A live webcast of Mesoblast's presentation can be accessed via either <u>http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=19955</u> or <u>http://investorsmedia.mesoblast.com</u>

The archived webcast will be available in the Events and Presentations section of the Company's website via www.mesoblast.com.

About Mesoblast

Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a global leader in cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases where there are highly unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncology/hematology conditions.

For further information, please contact:

Julie Meldrum Global Head of Corporate Communications Mesoblast Limited T: +61 3 9639 6036 E: julie.meldrum@mesoblast.com

Mesoblast Limited ABN 68 109 431 870 www.mesoblast.com Corporate Headquarters Level 38 55 Collins Street Melbourne 3000

Victoria Australia **t** +61 3 9639 6036 **f** +61 3 9639 6030 United States Operations 505 Fifth Avenue Third Floor New York, NY 10017

USA T +1 212 880 2060

F +1 212 880 2001

Asia

20 Biopolis Way #05-01 Centros Biopreneur 3 SINGAPORE 138668

т +65 6570 0635 г +65 6570 0176